Precipio, Inc. Common Stock PRPO

Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

PRPO hizo una agrupación de acciones (split inverso) de 1:20 el 22 de septiembre de 2023: cada 20 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Zacks Investment Research 22 sept

  PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

  Both Precipio and Fulgent Genetics operate in specialty diagnostics with exposure to oncology, but Fulgent Genetics is recommended as the better investment choice. FLGT offers a more diversified growth platform through recent acquisitions (Bako Diagnostics, StrataDx), AI/digital pathology investments, and a therapeutic pipeline, while trading below its historical valuation median. PRPO shows improving fundamentals and cash generation but trades above its five-year median, suggesting its progress is already priced in.

  

• GlobeNewswire Inc. 12 jun

  Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

  Precipio Inc. (NASDAQ: PRPO) is urging shareholders to vote immediately to reach the 50% quorum requirement for its Annual Shareholders Meeting scheduled for June 15, 2026. As of the press release date, only 42% of shares had been voted. The company is seeking to avoid costly adjournment and rescheduling expenses if sufficient votes are not received by the June 14 deadline.

  

• GlobeNewswire Inc. 11 jun

  Precipio to Present at the Planet MicroCap Las Vegas

  Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will present at the Planet MicroCap Las Vegas 2026 conference on June 17, 2026. CEO Ilan Danieli and COO Zaki Sabet will host the presentation. The company emphasized it is profitable and focused on raising awareness and building its shareholder base rather than raising capital.